0000950170-24-062009.txt : 20240517
0000950170-24-062009.hdr.sgml : 20240517
20240517184221
ACCESSION NUMBER: 0000950170-24-062009
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240517
FILED AS OF DATE: 20240517
DATE AS OF CHANGE: 20240517
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ji Henry
CENTRAL INDEX KEY: 0001470981
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39852
FILM NUMBER: 24961912
MAIL ADDRESS:
STREET 1: 5370 RUETTE DE MER
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Scilex Holding Co
CENTRAL INDEX KEY: 0001820190
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 960 SAN ANTONIO ROAD
CITY: PALO ALTO
STATE: CA
ZIP: 94303
BUSINESS PHONE: (650) 516-4310
MAIL ADDRESS:
STREET 1: 960 SAN ANTONIO ROAD
CITY: PALO ALTO
STATE: CA
ZIP: 94303
FORMER COMPANY:
FORMER CONFORMED NAME: Scilex Holding Company/DE
DATE OF NAME CHANGE: 20221117
FORMER COMPANY:
FORMER CONFORMED NAME: Vickers Vantage Corp. I
DATE OF NAME CHANGE: 20200804
4
1
ownership.xml
4
X0508
4
2024-05-17
0001820190
Scilex Holding Co
SCLX
0001470981
Ji Henry
C/O SCILEX HOLDING COMPANY
960 SAN ANTONIO ROAD
PALO ALTO
CA
94303
true
true
false
false
Executive Chairperson
false
Common Stock
2024-05-17
4
P
false
50000
0.8797
A
50070
I
By BioVintage, Inc.
Common Stock
2749
I
By BioVintage, Inc.
Common Stock
305273
D
Common Stock
292264
I
See Footnote
Common Stock
5640
I
By Spouse
Open market purchase by the reporting person of 50,000 shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock reported represents an aggregate number of shares purchased in multiple open market transactions over a range of sales prices.
Reflects the weighted average price of the shares of Common Stock purchased on the open market in multiple transactions on May 17, 2024 at prices ranging from $0.8700 to $0.8800 per share, inclusive. The amount reflected has been rounded to 4 decimal points.
The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of such shares of Common Stock purchased at each separate price within such range.
On December 30, 2022, the Board of Directors of Sorrento Therapeutics, Inc. ("Sorrento") declared a stock dividend (the "Dividend") to all holders of record of its common stock as of the close of business on January 9, 2023, of 0.1410127 of a share of Common Stock for each one share of common stock, par value $0.0001 per share, of Sorrento ("Sorrento Common Stock"). The reporting person wrote a put option in Sorrento Common Stock on August 26, 2022 (the "Put Option"), which was adjusted as a result of the Stock Dividend to relate to an aggregate of 19,500 shares of Sorrento Common Stock and 2,749 shares of Common Stock and to reflect a corresponding change to the exercise price of the Put Option to $0.80268 per share of Sorrento Common Stock and $8.6002 per share of Common Stock.
(Continued from footnote 4 ) The Put Option settled on March 17, 2023 and resulted in the reporting person becoming entitled to receive 2,749 shares of Common Stock at a price of $8.6002 per share of Common Stock, upon the expiration of the lock-up on such shares which is currently set to expire on September 30, 2024.
Shares are held in family trusts of which the reporting person is a co-trustee with his spouse.
/s/ Jaisim Shah, as Attorney-in-Fact
2024-05-17